---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102399"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:58:30.793054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025

## Summary
- Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.
- Positive ORIGIN 3 trial: 46% proteinuria reduction with atacicept; 42% vs placebo (p<0.0001).
- BLA submission for accelerated approval of atacicept in IgAN expected Q4 2025; commercial launch targeted 2026.
- Secured up to $500M credit facility with Oxford Finance, extending cash runway past potential launch.
- Initiated PIONEER basket trial for atacicept in expanded IgAN, pMN, FSGS, and MCD populations.

## SEC filing metadata
- accession: 0000950170-25-102399
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/0000950170-25-102399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102399
- JSON: https://secwatch.observer/filing/0000950170-25-102399.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.